Chemotherapy for colorectal cancer has become more complicated and diversified with the
appearance of molecular‐targeting agents. 5‐Fluorouracil (5‐FU) has been a mainstay of …

fluorouracil (5-FU) is an important antineoplastic agent that has proven to be effective in the
treatment of colorectal cancer. However, one of the main obstacles to the clinical use of 5-FU …

The pyrimidine trifluorothymidine (TFT) inhibits thymidylate synthase (TS) and can be
incorporated into the DNA. TFT, as part of TAS‐102, is clinically evaluated in phase II studies …

Thymidylate synthase (TS) is a dNTP synthetic enzyme and is also a target enzyme of 5-
fluorouracil (5-FU). 5-FU is one of the anticancer agents most frequently used for the …

Bevacizumab (Bv) can be used synergistically with fluoropyrimidine‐based chemotherapy to
treat colorectal cancer. Whether and how it affects the delivery of fluoropyrimidine drugs is …

Abstract Lessons Learned The upregulation of dihydropyrimidine dehydrogenase (DPD)
and thymidylate synthase (TS) are important mechanisms of resistance to 5‐fluorouracil (5 …

In colorectal cancer chemotherapy, the current standard of care includes combination
therapy with 5-fluorouracil (5-FU) and leucovorin (LV). However, the factors that determine …

Combination of MEK inhibitor and 5-FU had showed limited efficacy in clinical trials. We
previously reported that acquired resistance to 5-FU was related with continued activation of …

Recently, evidence has accumulated that weekly 24-h infusion of high-dose 5-fluorouracil (5-
FU) with leucovorin (LV, folinic acid) biochemical modulation may improve the response …

This study was designed to explore the possible interaction of 5-fluorouracil (5-FU) and 7-
ethyl-10-hydroxycamptothecin (SN-38) in vitro. Human colon cancer LoVo cells were treated …